Diabetes Archives - Page 114 of 119 - Renal and Urology News


U.K. Team: GFR Estimates Important

SAN FRANCISCO—British researchers have endorsed U.S. guidelines stating that screening diabetic patients for renal disease should involve estimated glomerular filtration rate (eGFR) in addition to testing for albuminuria.

Study Probes Costs of Diabetic Neuropathy

WASHINGTON, D.C.—Diabetics with neuropathy use more health- care resources than diabetics without this complication. In addition, among patients with diabetic neuropathy, those with comorbid depression or anxiety incur higher health-care costs than patients without these psychological problems.

Fixed-Dose Combination Tablet Approved for Type 2 Diabetes

Sciele Pharma, Inc., of Atlanta and Novo Nordisk Inc., of Denmark, have announced approval for PrandiMet (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the fast-acting secretagogue replaglinide (also called Prandin) and the insulin sensitizer metformin for the treatment of type 2 diabetes.

Experimental Drug Benefits Type 2 Diabetics

SAN FRANCISCO—New results from a phase III trial demonstrate that the investigational once-weekly formulation of exenatide, an incretin mimetic agent, provides sustained glucose control and weight loss for at least 52 weeks in patients with type 2 diabetes.

Oral Diabetes Drugs Suffice Long Term

SAN FRANCISCO—Most patients with type 2 diabetes may be able to control their disease for up to 15 years and still avoid insulin injections by using multiple classes of oral diabetic medications.

Novel Oral Diabetes Drug Promising

SAN FRANCISCO—The investigational agent saxagliptin, which belongs to a new class of anti-diabetic drugs that is taken orally rather than by injection, is effective and safe in treatment-naïve, type 2 diabetics with inadequate glycemic control, new findings suggest.

Renoprotective Effect of Aliskiren Shown

Aliskiren, an oral direct renin inhibitor, may have renoprotective effects that are independent of its BP-lowering effect in patients with type 2 diabetic nephropathy who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy, researchers report.

Next post in News